or Try an Advanced Search...

    Technical Analysis for THAR - Tharimmune, Inc.

    Grade Last Price % Change Price Change
    F 4.75 5.69% 0.26
    THAR closed up 5.69 percent on Friday, May 31, 2024, on 2.57 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical THAR trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    New 52 Week Closing Low Bearish 5.69%
    Calm After Storm Range Contraction 5.69%
    Lower Bollinger Band Walk Weakness 5.69%
    Inside Day Range Contraction 5.69%
    Wide Bands Range Expansion 5.69%
    Older End-of-Day Signals for THAR ...

       Recent Intraday Alerts

    Alert Time
    Down 3% 2 days ago
    Fell Below Previous Day's Low 2 days ago
    Down 2 % 2 days ago
    Down 1% 2 days ago
    Lower Bollinger Band Support 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    THAR Chart by TradingView
    Basic chart:

    Profile

    Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis

    Is THAR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 22 Tharimmune Announces 1-for-15 Reverse Stock Split
    May 2 Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
    Apr 23 Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
    Apr 15 Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
    Mar 6 Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
    Mar 5 Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
    Feb 20 Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
    Feb 5 Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
    Jan 29 Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
    Dec 19 Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
    See more THAR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 163.0875
    52 Week Low 4.15
    Average Volume 22,202
    200-Day Moving Average 31.89
    50-Day Moving Average 5.78
    20-Day Moving Average 5.33
    10-Day Moving Average 4.99
    Average True Range 0.52
    RSI (14) 55.56
    ADX 15.35
    +DI 34.99
    -DI 13.80
    Chandelier Exit (Long, 3 ATRs) 4.90
    Chandelier Exit (Short, 3 ATRs) 5.70
    Upper Bollinger Bands 6.32
    Lower Bollinger Band 4.34
    Percent B (%b) 0.21
    BandWidth 37.30
    MACD Line -0.30
    MACD Signal Line -0.23
    MACD Histogram -0.075
    Fundamentals Value
    Market Cap 11.98 Million
    Num Shares 2.53 Million
    EPS -15.50
    Price-to-Earnings (P/E) Ratio -0.31
    Price-to-Sales 0.00
    Price-to-Book 0.67
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.05
    Resistance 3 (R3) 6.05 5.62 5.83
    Resistance 2 (R2) 5.62 5.29 5.62 5.76
    Resistance 1 (R1) 5.18 5.08 5.40 5.18 5.69
    Pivot Point 4.75 4.75 4.86 4.75 4.75
    Support 1 (S1) 4.31 4.42 4.53 4.31 3.80
    Support 2 (S2) 3.88 4.21 3.88 3.73
    Support 3 (S3) 3.44 3.88 3.66
    Support 4 (S4) 3.44